leadf
logo-loader
viewGlaxoSmithKline PLC

GlaxoSmithKline's shingles vaccine filed in Europe

Most sufferers are afflicted with a rash, but in the severest cases the disease can cause blindness and intense pain.

picture of someone scratching
Shingles is a disease of the nervous system

GlaxoSmithKline PLC (LON:GSK) has applied for approval for its new over-50s shingles vaccine in Europe to follow its submission in the US last month.

Shingrix came through a final phase III study with flying colours.

In the study, Shingrix showed a 90% efficacy in adults aged 70 and older that was maintained for four years. It also helped reduce the level of pain in sufferers

Shingles stems from the reactivation of the chicken pox virus VZV, with one in three people over the age of fifty likely to suffer and one in two over 85.

Most sufferers are afflicted with a rash, but in the severest cases the disease can cause blindness and intense pain.

The phase III trial evaluated the efficacy, safety and immunogenicity in doses two months apart. 

Dr Emmanuel Hanon, Glaxo’s head of Vaccines R&D, said the vaccine has consistently shown high efficacy in older people in its phase III development programme.

“Today's file submission puts us a step closer to making this vaccine available to help protect more people from shingles and the complications associated with it."

First revenues from the product are expected in 2018.

Shares rose 20p to 1,543p.

Quick facts: GlaxoSmithKline PLC

Price: 1380.2 GBX

LSE:GSK
Market: LSE
Market Cap: £69.25 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan signs UK government contract to development COVID-19 Human...

Open Orphan's (LON:ORPH) Chairman Cathal Friel talks to Proactive London after announcing a contract with the UK Government for the development of a COVID-19 human challenge study model. Friel explains that the company, hVIVO, is the world's leader in this sector, having safely run more human...

11 hours, 50 minutes ago

2 min read